Key Elements In Monitoring for Potential Adverse Events with Bispecific Antibodies
Medical experts dissect critical strategies for monitoring for potential adverse events with bispecific antibodies in a comprehensive panel discussion.
Stay updated with breaking news from Risk Stratification. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Medical experts dissect critical strategies for monitoring for potential adverse events with bispecific antibodies in a comprehensive panel discussion.
Considerations for enhancing bispecific drug effectiveness through strategic EMR utilization in healthcare are explored.
A panel discussion covers considerations within REMS programs aimed at minimizing risks associated with bispecific therapy. NOTE: Not all FDA-approved bispecific antibodies are associated with a REMS protocol.
Providers delve into considerations for continuation of optimal care when patients receiving bispecific therapy transition between care settings.
Michael D. Shapiro, DO, reviews and discusses the different guidelines and recommendations on Lp(a) testing.